MedTrace Logo

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

NCT01715233 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-03-15

Study results available
· View outcomes & findings →

Summary

To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.

Conditions

Interventions

DRUG

Docetaxel

Modified Docetaxel 40mg/m2 on Day 1

DRUG

Leucovorin

Leucovorin 400mg/m2 on Day 1

DRUG

Fluorouracil

Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2

DRUG

Cisplatin

Cisplatin (or Carboplatin) 40mg/m2 on Day 3

Sponsors & Collaborators

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Ronan J Kelly, MD, MBA · SKCCC at Johns Hopkins

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2015-06-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715233 on ClinicalTrials.gov